S100A9 and systemic sclerosis: Interestingly, we discovered that PQD, a selective S100A9/TRL4 binding blocker, has been approved by the FDA for treating systemic scleroderma and has shown safety and efficiency in clinical trials treating other autoimmune/inflammatory diseases.42, 48